U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515768) titled 'TAVI Without On-Site Cardiac Surgery in Poland: A Randomized Multicenter Trial Protocol' on March 31.
Brief Summary: Aortic stenosis (AS) represents the most prevalent acquired valvular heart disease in European populations, and transcatheter aortic valve implantation (TAVI) has become the dominant treatment modality for patients with symptomatic severe AS. The latest 2025 ESC guidelines have broadened age-related eligibility, while the procedure still continues to be limited to centres with cardiac surgery on-site (CSOS). This limitation is in place, despite the very low rate of complications requiring emergent surgical conversion....